Global Antibacterial Drugs Market 2023-2027

Description

List of Tables

The antibacterial drugs market is forecasted to grow by USD 9908.11 mn during 2022-2027, accelerating at a CAGR of 4.21% during the forecast period. The report on the antibacterial drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of bacterial infections, growing awareness of various diseases and their treatment caused by bacteria, and rising aging population globally.

Technavio's antibacterial drugs market is segmented as below:

Market Scope
Base Year	2022
End Year	2027
Series Year	2023-2027
Growth Momentum	Accelerate
YOY 2023	3.42%
CAGR	4.21%
Incremental Value	$9908.11mn

By Route Of Administration

Intravenous
Oral
Others

By Drug Class

B-lactam
Quinolones
Macrolides
Tetracyclines
Others

By Geography

Asia
North America
Europe
Rest of World (ROW)

This study identifies the application of nanotechnology in antibacterial drugs as one of the prime reasons driving the antibacterial drugs market growth during the next few years. Also, rising priorities for research and development of age-appropriate antibiotics and increasing number of partnerships and collaborations will lead to sizable demand in the market.

The report on the antibacterial drugs market covers the following areas:

Antibacterial drugs market sizing
Antibacterial drugs market forecast
Antibacterial drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antibacterial drugs market vendors that include AbbVie Inc., Basilea Pharmaceutica Ltd., Bayer AG, Binnopharm Group LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Melinta Therapeutics LLC, and Shionogi and Co. Ltd.. Also, the antibacterial drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76198

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global antibacterial drugs market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global antibacterial drugs market 2017 - 2021 ($ million)
4.2 Route of administration Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Route of administration Segment 2017 - 2021 ($ million)
4.3 Drug class Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Drug class Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Intravenous - Market size and forecast 2022-2027
Exhibit 34: Chart on Intravenous - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Intravenous - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Intravenous - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Intravenous - Year-over-year growth 2022-2027 (%)
6.4 Oral - Market size and forecast 2022-2027
Exhibit 38: Chart on Oral - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Oral - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Oral - Year-over-year growth 2022-2027 (%)
6.5 Others - Market size and forecast 2022-2027
Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Route of Administration
Exhibit 46: Market opportunity by Route of Administration ($ million)
Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

7.1 Market segments
Exhibit 48: Chart on Drug Class - Market share 2022-2027 (%)
Exhibit 49: Data Table on Drug Class - Market share 2022-2027 (%)
7.2 Comparison by Drug Class
Exhibit 50: Chart on Comparison by Drug Class
Exhibit 51: Data Table on Comparison by Drug Class
7.3 B-lactam - Market size and forecast 2022-2027
Exhibit 52: Chart on B-lactam - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on B-lactam - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on B-lactam - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on B-lactam - Year-over-year growth 2022-2027 (%)
7.4 Quinolones - Market size and forecast 2022-2027
Exhibit 56: Chart on Quinolones - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Quinolones - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Quinolones - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Quinolones - Year-over-year growth 2022-2027 (%)
7.5 Macrolids - Market size and forecast 2022-2027
Exhibit 60: Chart on Macrolids - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Macrolids - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Macrolids - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Macrolids - Year-over-year growth 2022-2027 (%)
7.6 Tetracyclins - Market size and forecast 2022-2027
Exhibit 64: Chart on Tetracyclins - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Data Table on Tetracyclins - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Chart on Tetracyclins - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Tetracyclins - Year-over-year growth 2022-2027 (%)
7.7 Others - Market size and forecast 2022-2027
Exhibit 68: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 71: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.8 Market opportunity by Drug Class
Exhibit 72: Market opportunity by Drug Class ($ million)
Exhibit 73: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 75: Chart on Market share by geography 2022-2027 (%)
Exhibit 76: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.4 North America - Market size and forecast 2022-2027
Exhibit 83: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.5 Europe - Market size and forecast 2022-2027
Exhibit 87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 95: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 China - Market size and forecast 2022-2027
Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 Japan - Market size and forecast 2022-2027
Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.11 UK - Market size and forecast 2022-2027
Exhibit 111: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 112: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 113: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 114: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 115: Market opportunity by geography ($ million)
Exhibit 116: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 123: AbbVie Inc. - Overview
Exhibit 124: AbbVie Inc. - Product / Service
Exhibit 125: AbbVie Inc. - Key news
Exhibit 126: AbbVie Inc. - Key offerings
12.4 Bayer AG
Exhibit 127: Bayer AG - Overview
Exhibit 128: Bayer AG - Business segments
Exhibit 129: Bayer AG - Key news
Exhibit 130: Bayer AG - Key offerings
Exhibit 131: Bayer AG - Segment focus
12.5 Bristol Myers Squibb Co.
Exhibit 132: Bristol Myers Squibb Co. - Overview
Exhibit 133: Bristol Myers Squibb Co. - Product / Service
Exhibit 134: Bristol Myers Squibb Co. - Key news
Exhibit 135: Bristol Myers Squibb Co. - Key offerings
12.6 Cipla Ltd.
Exhibit 136: Cipla Ltd. - Overview
Exhibit 137: Cipla Ltd. - Business segments
Exhibit 138: Cipla Ltd. - Key news
Exhibit 139: Cipla Ltd. - Key offerings
Exhibit 140: Cipla Ltd. - Segment focus
12.7 Eli Lilly and Co.
Exhibit 141: Eli Lilly and Co. - Overview
Exhibit 142: Eli Lilly and Co. - Product / Service
Exhibit 143: Eli Lilly and Co. - Key news
Exhibit 144: Eli Lilly and Co. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 150: GlaxoSmithKline Plc - Overview
Exhibit 151: GlaxoSmithKline Plc - Business segments
Exhibit 152: GlaxoSmithKline Plc - Key news
Exhibit 153: GlaxoSmithKline Plc - Key offerings
Exhibit 154: GlaxoSmithKline Plc - Segment focus
12.10 Kyorin Pharmaceutical Co. Ltd.
Exhibit 155: Kyorin Pharmaceutical Co. Ltd. - Overview
Exhibit 156: Kyorin Pharmaceutical Co. Ltd. - Product / Service
Exhibit 157: Kyorin Pharmaceutical Co. Ltd. - Key offerings
12.11 Lupin Ltd.
Exhibit 158: Lupin Ltd. - Overview
Exhibit 159: Lupin Ltd. - Product / Service
Exhibit 160: Lupin Ltd. - Key news
Exhibit 161: Lupin Ltd. - Key offerings
12.12 Merck KGaA
Exhibit 162: Merck KGaA - Overview
Exhibit 163: Merck KGaA - Business segments
Exhibit 164: Merck KGaA - Key news
Exhibit 165: Merck KGaA - Key offerings
Exhibit 166: Merck KGaA - Segment focus
12.13 Novartis AG
Exhibit 167: Novartis AG - Overview
Exhibit 168: Novartis AG - Business segments
Exhibit 169: Novartis AG - Key offerings
Exhibit 170: Novartis AG - Segment focus
12.14 Paratek Pharmaceuticals Inc.
Exhibit 171: Paratek Pharmaceuticals Inc. - Overview
Exhibit 172: Paratek Pharmaceuticals Inc. - Product / Service
Exhibit 173: Paratek Pharmaceuticals Inc. - Key offerings
12.15 Pfizer Inc.
Exhibit 174: Pfizer Inc. - Overview
Exhibit 175: Pfizer Inc. - Product / Service
Exhibit 176: Pfizer Inc. - Key news
Exhibit 177: Pfizer Inc. - Key offerings
12.16 Sanofi
Exhibit 178: Sanofi - Overview
Exhibit 179: Sanofi - Business segments
Exhibit 180: Sanofi - Key news
Exhibit 181: Sanofi - Key offerings
Exhibit 182: Sanofi - Segment focus
12.17 Teva Pharmaceutical Industries Ltd.
Exhibit 183: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 184: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 185: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 186: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 187: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 188: Inclusions checklist
Exhibit 189: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 190: Currency conversion rates for US$
13.4 Research methodology
Exhibit 191: Research methodology
Exhibit 192: Validation techniques employed for market sizing
Exhibit 193: Information sources
13.5 List of abbreviations
Exhibit 194: List of abbreviations